Bone Metabolism Tests Market Report 2026

The bone metabolism tests market size has grown strongly in recent years. It will grow from $2.06 billion in 2025 to $2.23 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to rising prevalence of osteoporosis, increased clinical awareness of metabolic bone disorders, wider availability of biochemical testing assays, growth in hospital-based diagnostic services, adoption of bone density screening programs.

The bone metabolism tests market size is expected to see strong growth in the next few years. It will grow to $3.02 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing aging population, growing demand for personalized bone health assessment, expansion of clinical research on bone diseases, rising use of molecular diagnostics, increasing integration of laboratory automation. Major trends in the forecast period include increasing adoption of advanced bone turnover biomarker panels, rising use of automated immunoassay platforms, growing integration of molecular bone metabolism testing, expansion of bone health monitoring in drug development, enhanced focus on early osteoporosis detection.

The increasing prevalence of osteoporosis and osteopenia is expected to drive the growth of the bone metabolism tests market going forward. Osteoporosis and osteopenia are musculoskeletal disorders marked by low bone density and deterioration of bone tissue, resulting in greater fragility and higher fracture risk, especially among older adults. The prevalence of these conditions is rising as aging populations experience accelerated bone loss, leading to reduced bone strength. Bone metabolism tests assist in detecting and monitoring osteoporosis and osteopenia by assessing markers of bone formation and resorption. They provide critical insights into bone turnover, supporting early intervention and informed treatment planning. For instance, in February 2024, according to Arthritis Australia, an Australia-based non-profit organization, osteoarthritis (OA) is projected to affect 2.35 million Australians in 2025, representing 57% of the total arthritis population and making it the most common form of arthritis in the country. By 2040, the number of Australians with OA is expected to reach 3.11 million, a 32% increase from 2025, corresponding to an additional 762,515 people living with OA in Australia by 2040 compared with 2025. Therefore, the growing prevalence of osteoporosis and osteopenia is fueling the growth of the bone metabolism tests market.

The increasing emphasis on personalized medicine is expected to further propel the growth of the bone metabolism tests market. Personalized medicine involves tailoring medical treatments to an individual’s biological characteristics, such as genetic markers and biomarkers. Its growth is driven by advancements in molecular diagnostics, which enable more accurate patient profiling and targeted therapeutic decisions. Bone metabolism tests facilitate personalized medicine by providing biochemical markers that help clinicians customize care for osteoporosis and other metabolic bone disorders. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based professional healthcare organization, the FDA approved 16 new personalized therapies for rare-disease patients in 2023, up from six approvals in 2022. Therefore, the rising focus on personalized medicine is supporting the growth of the bone metabolism tests market.

In February 2025, SimonMed, a US-based outpatient medical imaging provider, partnered with HeartLung Technologies to advance bone health through AI-powered early detection. The collaboration aims to improve preventive care by enabling nationwide, radiation-free bone density screening using AI-driven analysis of existing CT scans. HeartLung Technologies is a US-based provider of imaging-based bone density screening.

Major companies operating in the bone metabolism tests market are F. Hoffmann-La Roche AG, Abbott Laboratories, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Hologic Inc., QuidelOrtho Corporation, Beckman Coulter Inc., Bio-Rad Laboratories Inc., DiaSorin S.p.A., Randox Laboratories Ltd., Trivitron Healthcare Pvt. Ltd., MESO SCALE DIAGNOSTICS LLC, Immunodiagnostic Systems plc, DMS Imaging SA, Creative Diagnostics, Oxford Biosystems Ltd., Epitope Diagnostics Inc., Maccura Biotechnology Co. Ltd., Ortho Clinical Diagnostics, Fujirebio Diagnostics Inc., Sysmex Corporation.

North America was the largest region in the bone metabolism tests market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bone metabolism tests market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bone metabolism tests market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the bone metabolism tests market by increasing costs of imported assay reagents, diagnostic instruments, laboratory consumables, and automated immunoassay systems used in hospitals and diagnostic laboratories. North America and Europe are most affected due to reliance on imported diagnostic technologies, while Asia-Pacific faces higher costs for advanced testing platforms. These tariffs are increasing testing expenses and slowing equipment upgrades. However, they are also encouraging domestic reagent manufacturing, local instrument assembly, and regional diagnostic innovation, supporting long-term supply chain stability.

The bone metabolism tests market research report is one of a series of new reports that provides bone metabolism tests market statistics, including bone metabolism tests industry global market size, regional shares, competitors with a bone metabolism tests market share, detailed bone metabolism tests market segments, market trends and opportunities, and any further data you may need to thrive in the bone metabolism tests industry. This bone metabolism tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bone metabolism tests are laboratory assessments that evaluate the balance between bone formation and bone breakdown. These tests measure specific markers in blood or urine, such as alkaline phosphatase and osteocalcin for bone formation, and CTX or NTX for bone resorption, to assess bone health, diagnose metabolic bone disorders, and monitor treatment effectiveness.

The main types of bone metabolism tests are biochemical tests, imaging tests, bone density tests, histomorphometry, and molecular testing. Biochemical tests measure markers in blood or urine that reflect bone turnover, while imaging and bone density tests assess bone structure and mineral content. The products include assays, consumables, and instruments utilizing various technologies such as enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), and others. These tests are applied across multiple areas, including osteoporosis diagnosis, bone disease evaluation, fracture risk assessment, drug development, and clinical research, serving end users such as hospitals, diagnostic laboratories, research institutes, home care settings, and academic institutions.

The bone metabolism tests market consists of revenues earned by entities by providing services such as sample collection and processing, test result interpretation, patient screening consultations, diagnostic panel customization, and remote test accessibility. The market value includes the value of related goods sold by the service provider or included within the service offering. The bone metabolism tests market includes sales of analyzers, calibration standards, patient-specific reporting software, quality control reagents, and at-home test kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.